ARSD

Across TCGA pan-cancer cohorts, ARSD mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARSD data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ARSD mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARSD expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

OV, PDAC, and CCRCC are the cancer types where ARSD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.669	1.000	.015	12	view →
PDAC	OS	Median	III,IV	0.550	0.328	.043	4	view →
CCRCC	OS	Tertile	III,IV	0.910	0.592	.016	2	view →
LUAD	DFS	Quartile	All	0.884	0.950	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARSD–OV (DFS)

Open the OV breakdown →